Publications scientifiques
Les activités scientifiques de GeNeuro reposent sur plus de 25 années de recherche, effectuée en interne et en collaboration avec des groupes universitaires renommés.
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study
MS Journal, July 9, 2021
https://geneuro.ch/data/news/MSJ-July-21-Efficacy-and-safety-of-temelimab-in-multiple-sclerosis.pdf
pHERV-W envelope protein fuels microglial cell-dependent damage of myelinated axons in multiple sclerosis
PNAS, July 23, 2019
A High-dose Pharmacokinetic Study of a New IgG4 Monoclonal Antibody Temelimab/GNbAC1 Antagonist of an Endogenous Retroviral Protein pHERV-W Env
Clinical Therapeutics, July 13, 2019
https://www.clinicaltherapeutics.com/article/S0149-2918(19)30296-6/pdf
ECTRIMS 2109 – Neuroprotective effects of temelimab in relapsing-remitting MS patients extend to 96 weeks
Phase IIb safety and efficacy data on temelimab at week 96 from the ANGEL-MS study
Neural Cell Responses Upon Exposure to Human Endogenous Retroviruses
Frontiers in Genetics, July 11, 2019
https://www.frontiersin.org/articles/10.3389/fgene.2019.00655/full